Remedium Lifecare Yönetim

Yönetim kriter kontrolleri 1/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Adarsh Munjal

İcra Kurulu Başkanı

₹2.0m

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	1.2yrs
CEO sahipliği	n/a
Yönetim ortalama görev süresi	Veri yok
Yönetim Kurulu ortalama görev süresi	less than a year

Son yönetim güncellemeleri

Recent updates

CEO

Adarsh Munjal (36 yo)

1.2yrs

Görev süresi

₹1,978,226

Tazminat

Mr. Adarsh Munjal is Whole Time Director of Remedium Lifecare Limited from September 5, 2023. Mr. Adarsh Munjal is a BMM-graduate from Jai Hind College (Mumbai University) with over 15 years of experience...

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Adarsh Munjal	Whole Time Director	1.2yrs	₹1.98m	Veri yok
Pratik Shah	Independent Director	less than a year	Veri yok	Veri yok
Seema Sanei	Independent Director	less than a year	Veri yok	Veri yok

0.6yrs

Ortalama Görev Süresi

36yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 539561 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 0.6 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.

Remedium Lifecare Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

High number of new and inexperienced directors

Remedium Lifecare Limited Appoints Neeraj Ramashankar Yadav as Whole Time Company Secretary and Compliance Officer

Remedium Lifecare Limited Announces the Resignation of Dhwani Desai as Company Secretary and Compliance Officer

Remedium Lifecare Limited, Annual General Meeting, Jun 26, 2024

Less than half of directors are independent

Remedium Lifecare Limited Appoints Dhwani Desai as Whole Time Company Secretary and Compliance Officer

Recent updates

Second quarter 2025 earnings released: EPS: ₹0.04 (vs ₹0.16 in 2Q 2024)

Remedium Lifecare Limited to Report Q2, 2025 Results on Nov 14, 2024

High number of new and inexperienced directors

Investor sentiment improves as stock rises 16%

Investor sentiment deteriorates as stock falls 15%

Remedium Lifecare to Consider Acquisition of Airowater Global Trading

Remedium Lifecare to Consider Acquisition of Airowater Global Trading

First quarter 2025 earnings released: EPS: ₹0.16 (vs ₹0.15 in 1Q 2024)

Remedium Lifecare Limited Appoints Neeraj Ramashankar Yadav as Whole Time Company Secretary and Compliance Officer

Investor sentiment deteriorates as stock falls 22%

Investor sentiment deteriorates as stock falls 22%

Remedium Lifecare Limited to Report Q1, 2025 Results on Aug 08, 2024

Investor sentiment improves as stock rises 21%

Remedium Lifecare Limited Announces the Resignation of Dhwani Desai as Company Secretary and Compliance Officer

Remedium Lifecare Limited, Annual General Meeting, Jun 26, 2024

Full year 2024 earnings released: EPS: ₹90.92 (vs ₹0.54 in FY 2023)

Investor sentiment deteriorates as stock falls 16%

Remedium Lifecare Limited to Report Q4, 2024 Results on May 10, 2024

Less than half of directors are independent

Investor sentiment deteriorates as stock falls 21%

Investor sentiment improves as stock rises 43%

Third quarter 2024 earnings released: EPS: ₹34.12 (vs ₹0.76 in 3Q 2023)

Remedium Lifecare Limited to Report Nine Months, 2024 Results on Feb 14, 2024

New minor risk - Share price stability

Remedium Lifecare Limited Appoints Dhwani Desai as Whole Time Company Secretary and Compliance Officer

New minor risk - Profit margin trend

Remedium Lifecare Limited Announces Resignation of Ashvini Dhuri as Company Secretary / Compliance Officer

Remedium Lifecare Limited Announces the Resignation of Dr. Vilas Ramkrishna Lokhande from the Position of Whole Time Director

Remedium Lifecare Limited to Report Q1, 2024 Results on Aug 12, 2023

New minor risk - Market cap size

Remedium Lifecare Limited, Annual General Meeting, Jul 20, 2023

New minor risk - Share price stability

Full year 2023 earnings released: EPS: ₹15.07 (vs ₹2.99 in FY 2022)

Remedium Lifecare Limited to Report Q4, 2023 Results on May 30, 2023

Investor sentiment improves as stock rises 22%

Investor sentiment improves as stock rises 27%

Investor sentiment deteriorates as stock falls 15%

Third quarter 2023 earnings released

Remedium Lifecare Limited to Report Q3, 2023 Results on Feb 07, 2023

Investor sentiment improved over the past week

Remedium Lifecare Limited (BSE : 539561) entered into an Memorandum of Understanding to acquire Mvk Lifesciences Private Limited.

Second quarter 2023 earnings released: EPS: ₹6.08 (vs ₹3.06 in 2Q 2022)

Remedium Lifecare Limited to Report Q2, 2023 Results on Nov 04, 2022

Remedium Lifecare Limited, Annual General Meeting, Sep 20, 2022

First quarter 2023 earnings released

Full year 2022 earnings released

Remedium Lifecare Limited to Report Q4, 2022 Results on May 30, 2022

Less than half of directors are independent

Third quarter 2022 earnings: Revenues in line with analyst expectations

Remedium Lifecare Limited to Report Q3, 2022 Results on Feb 09, 2022

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

Woman Independent Director recently bought ₹487k worth of stock

Company Secretary & Compliance Officer Nishant Phadtare has left the company

First quarter 2022 earnings released

Investor sentiment improved over the past week

Remedium Lifecare Limited to Report Q3, 2020 Results on Feb 12, 2021

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

New 90-day high: ₹50.00

Investor sentiment improved over the past week

New 90-day high: ₹32.80

Investor sentiment improved over the past week

New 90-day low: ₹29.45

Remedium Lifecare Limited to Report Q2, 2021 Results on Nov 13, 2020

Roxy Exports Limited Approves Appointment of Ms. Trupti Bolke as an Independent Director

Full year earnings released - EPS ₹0.77